Insmed Halts HS Program After Failed Trial

Insmed Inc. shares fell ~2% in after‑hours trading on 8 April 2026 after announcing discontinuation of its hidradenitis suppurativa program.
The Phase 2b CEDAR study of brensocatib (10 mg and 40 mg) failed to meet primary and secondary efficacy endpoints versus placebo.
At week 16, lesion count reductions were 45.5% (10 mg) and 40.3% (40 mg) versus 57.1% for placebo, indicating inferior efficacy.
Treatment‑emergent adverse events occurred in 55.4% (10 mg), 42.9% (40 mg) and 45.7% (placebo), with no new safety signals identified.